tbuckley/cabot-search huggingface dataset:
AB0297 Real-Life Effectiveness of Golimumab in Biologic-Naïve Rheumatoid Arthritis Patients – Data from reuma.pt, A Portuguese Registry
Authors: A.F. Mourão, C. Ribeiro, J. Borges, M.J. Gonçalves, M. Bernardes, S. Fernandes, R. Dezerto, P.A. Laires, P. Machado, M. Eusébio, M.J. Santos, H. Canhão
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Registries are becoming an increasingly important source of data, providing additional information on the use of biologics in clinical practice. The real-world clinical data currently available regarding the use of SC anti-TNFs is still limited. Therefore, it is of utmost importance to increase the knowledge of Golimumab (GLM) effectiveness in the clinical practice. <h3>Objectives</h3> This study was designed to access the effectiveness of SC GLM 50 mg/monthly + MTX through 52 weeks of treatment in biologic-naïve RA patients. The primary objective was to investigate the proportion of patients achieving clinical remission (DAS28ESR&lt;2.6). The secondary objectives were the evaluation of: the treatment persistence rates; the proportion of patients achieving functional response (ΔHAQ&gt;0.22); and the effect of treatment on DAS28 individual components. <h3>Methods</h3> This was a retrospective non-interventional study based on the Rheumatic Diseases Portuguese Register (Reuma.pt). It was conducted in a cohort of patients aged &gt;18 years with active RA despite previous treatment with conventional DMARDs, biologic-naïve, who started SC GLM+MTX, from March 2011 to August 2015. The cumulative incidence of achieving clinical remission, treatment persistence and functional response/remission were estimated using survival analysis. Cox regression was used to calculate the hazard ratios. <h3>Results</h3> A total of 109 patients (86.3% female, mean age 55.5±13.2 years; mean age of diagnosis 45.5±13.5 years, rheumatoid factor 78% positive) met the study criteria. Ninety-three had a follow up of at least 52 weeks (i.e. all patients who started treatment before August 2014). At week 52, 38.3% of patients were on clinical remission, 91.9% achieved functional response and 35.2% were on functional remission (HAQ&lt;0.5). The treatment persistence rate was 75.3% for the individuals who were in the study for ≥52 weeks (Figure 1). For functional remission, high CRP levels at baseline seem to be a determining factor (HR=0.54, <i>p</i>=0.026). <h3>Conclusions</h3> This is the first Golimumab data analysis generated from the Portuguese registry Reuma.pt. Our results are in agreement with data from other national registries and demonstrate the long-term effectiveness and the high treatment persistence rates of GLM through 52 weeks. <h3>Disclosure of Interest</h3> A. F. Mourão Consultant for: Merck Sharp &amp; Dohme, C. Ribeiro: None declared, J. Borges: None declared, M. J. Gonçalves: None declared, M. Bernardes: None declared, S. Fernandes: None declared, R. Dezerto Employee of: Merck Sharp &amp; Dohme, P. A. Laires Employee of: Merck Sharp &amp; Dohme, P. Machado Employee of: Merck Sharp &amp; Dohme, M. Eusébio: None declared, M. J. Santos: None declared, H. Canhão: None declared
Characterization of an Immunodeficient Mucopolysaccharidosis Type I (MPS-I) Mouse Model Suitable for Preclinical Testing of Human Stem Cell and Gene Therapy.
Authors: Mayra F. Quito-Rivera, Leah E. Colvin-Wanshura, Matthew S. Nelson, Zhenhong Nan, Shaukat A. Khan, Tyson B. Rogers, Indrani Maitra, Walter C. Low, Pankaj Gupta
Journal: Blood (2005)
Reply
Authors: Gherardo Finocchiaro, Michael Papadakis, Jan-Lukas Robertus, Harshil Dhutia, Alexandros Klavdios Steriotis, Maite Tome, Greg Mellor, Ahmed Merghani, Aneil Malhotra, Elijah Behr, Sanjay Sharma, Mary N. Sheppard
Journal: Journal of the American College of Cardiology (2016)
SAT0590 Pneumococcal Vaccination in Patients with Rheumatoid Arthritis – Results of A Claims Data Analysis
Authors: J. Callhoff, A. Luque Ramos, F. Hoffmann, A. Zink, K. Albrecht
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Due to autoinflammation and immunosuppressive therapy, patients with rheumatoid arthritis (RA) are at increased risk of developing pneumonia. The German Standing Vaccination Committee recommends standard vaccination against pneumococcal infections from age 60 onwards and for all persons with an increased health risk [1]. In patients with immunosuppression, booster vaccination is recommended every 5 years. <h3>Objectives</h3> To assess the vaccination status for pneumonia and the prevalence of hospitalised pneumonia in patients with RA and unaffected population controls in Germany using claims data. <h3>Methods</h3> This cross sectional study based on data of a large German statutory health insurance fund (Barmer GEK). The members had to be continuously insured between 2009 and 2013 and had to be between 18 and 99 years old. Insurants who had a diagnosis of RA (ICD-10 codes M05 or M06) in at least two quarters of the year 2013 were matched by age and sex in a ratio of 1: 5 to members without RA. Pneumococcal vaccination (once between 2009 and 2013) was evaluated with regard to age, sex, comorbidities, biologic treatment, primary or rheumatologic care and region of residence. Prevalences of inpatient pneumonia were compared to regional vaccination rates. <h3>Results</h3> The data of 111,482 RA patients and 557,410 matched controls were available for analysis. The mean age was 66.2 years and 79.7% were female. Compared to controls, RA patients were vaccinated more frequently (15.0% vs. 10.0%). Vaccination rates were comparable between male and female insurants and increased with older age. In proportion, RA patients &lt;60 years were vaccinated 4–11 times and patients &gt;60 years 1.2–1.5 times more frequently than controls. In East Germany, pneumonia vaccination rates were highest, the lowest rates were found in Southern Germany. Inpatient pneumonia prevalence was 2–3 times higher in RA patients compared to controls and tended to be higher in regions with low vaccination rates. <h3>Conclusions</h3> The increased pneumonia prevalence in RA patients confirms their status as a risk group. In consequence, they are vaccinated more frequently than controls, especially if they do not meet the generally recommended age criterion or if other additional risk factors are present. Overall, vaccination rates are still low. Historically, vaccination was performed more frequently in East Germany due to stricter regulations, and the lower pneumonia prevalences in these areas indicate that consequent vaccination may help to reduce pneumonia in RA. <h3>References</h3> Wiese-Posselt M1, Tertilt C, Zepp F. Vaccination recommendations for Germany. Dtsch Arztebl Int. 2011 Nov;108(45):771–9. <h3>Acknowledgement</h3> This study was funded by the German Federal Ministry of Education and Research (01EC1405). <h3>Disclosure of Interest</h3> None declared
The Nurses’ Health Study Takes Fresh Aim at Breast Cancer as It Heads Into Decade Five
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0491 A Novel Method of Estimating Extra-Renal Clearance of Uric Acid
Authors: D. Hyndman, S. Liu, J. Hall, J.N. Miner
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Serum uric Acid (sUA) concentration is a function of uric acid production and both renal and extra-renal clearance. Decreased renal clearance is well understood as a contributing factor in gout. Extra-renal clearance, however, has not been as well characterized. Estimating extra-renal clearance would allow the classification of patients with gout as having high or low extra-renal clearance. Additionally, since production must equal the sum of urinary excretion and extra-renal elimination, determining the amount of extra-renal elimination would allow estimation of the rate of uric acid production. With this information, subjects could be characterized by all three parameters that determine sUA levels. <h3>Objectives</h3> To estimate the extra-renal uric acid clearance of patients with gout. <h3>Methods</h3> sUA and 24-hour urinary uric acid excretion (24hrUUE) were measured in 30 patients with gout in the absence and presence of a specific URAT1 inhibitor that lowers uric acid by increasing renal uric acid excretion. In these patients, at least a 1 mg/dl decrease in sUA was achieved with the URAT1 inhibitor at steady state. Extra-renal clearance was calculated by dividing the drug-induced increase in 24hrUUE by the drug-induced decrease in sUA and adjusting units to yield ml/min. This calculation was performed twice for each patient as two sets of measurements for each patient were taken. The two calculated clearance values were then averaged. <h3>Results</h3> The average estimated extra-renal clearance of the 30 patients with gout was 4.4 ml/min. Maximum extra-renal clearance was 16 ml/min, while some patients apparently had no measurable extra-renal elimination (Figure). <h3>Conclusions</h3> Estimated extra-renal elimination varies greatly among patients with gout. Some patients have very low estimated extra-renal clearance which likely contributes to high sUA concentration. <h3>Acknowledgement</h3> Research sponsored by Ardea Biosciences/AstraZeneca. Editorial support was provided by PAREXEL and funded by AstraZeneca. <h3>Disclosure of Interest</h3> D. Hyndman Employee of: Ardea Biosciences, Inc., S. Liu Employee of: Ardea Biosciences, Inc., J. Hall Employee of: Ardea Biosciences, Inc., J. Miner Employee of: Ardea Biosciences, Inc.
18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse
Authors: Alessandro Broccoli, Lucia Zanoni, Cristina Nanni, Giancarlo Montini, Vittorio Stefoni, Cinzia Pellegrini, Letizia Gandolfi, Cristina Fonti, Filippo Lodi, Michele Cavo, Stefano Fanti, Pier Luigi Zinzani
Journal: Blood (2015)
Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Authors: Rafael Caparica, Cheng Tzu Yen, Renata Coudry, Sai-Hong Ignatius Ou, Marileila Varella-Garcia, D. Ross Camidge, Gilberto de Castro
Journal: Journal of Thoracic Oncology (2016)
“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction
Authors: Senthil Selvaraj, Deepak L. Bhatt, Gregg W. Stone, C. Michael Gibson, Ph. Gabriel Steg, Christian W. Hamm, Matthew J. Price, Efthymios N. Deliargyris, Jayne Prats, Kenneth W. Mahaffey, Harvey D. White, Robert A. Harrington
Journal: Journal of the American College of Cardiology (2016)
FRI0047 Histamine and Histamine H4 Receptor Promotes Osteoclastogenesis in Rheumatoid Arthritis
Authors: H.-R. Kim, K.-A. Lee, K.-W. Kim, B.-M. Kim, S.-H. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The biological function of histamine is mediated through four types of histamine H1∼H4 receptors. Histamine H4 receptor (H4R) has immune-modulatory and chemotaxic effects and various immune cells express H4R. <h3>Objectives</h3> This study aimed to determine the osteoclastogenic role of H4R in rheumatoid arthritis (RA). <h3>Methods</h3> The expression of H4R in RA synovial fluid mononuclear cells (SFMCs), synovial fibroblasts and peripheral blood mononuclear cells (PBMCs) using real-time polymerase chain reaction (PCR). After RA SFMCs and PBMCs were treated with histamine, Th17 cytokines, such as IL-17, IL-21 and IL-22, and H4R antagonist (JNJ7777120), the gene expression and protein production of H4R and RANKL were determined by real-time PCR and ELISA. Osteoclastogenesis was assessed by counting tartrate-resistant acid phosphatase–positive multinucleated cells in peripheral blood CD14+ monocytes cultured with histamine, Th17 cytokines and JNJ7777120. <h3>Results</h3> The synovial fluid and serum concentration of histamine was higher in RA, compared with osteoarthritis and healthy controls, respectively. The expression of H4R was increased in RA PBMCs compared with healthy controls. Histamine, IL-17, IL-21 and IL-22 stimulated the expression of H4R and RANKL in PBMCs and JNJ7777120 reduced the histamine and Th17 cytokine-induced RANKL expression. Histamine and Th17 cytokines also induced the osteoclast differentiation from peripheral blood monocytes and JNJ7777120 decreased the osteoclastogenesis. <h3>Conclusions</h3> H4R mediates RANKL expression and osteoclast differentiation induced by histamine and Th17 cytokines. The blockage of H4R could be a new therapeutic modality for prevention of bone destruction in RA. <h3>Acknowledgement</h3> This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2015R1D1A1A01056763). <h3>Disclosure of Interest</h3> None declared
Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy.
Authors: Maurizio Arico, Maria Grazia Valsecchi, Carmelo Rizzari, Elena Barisone, Andrea Biondi, Fiorina Casale, Franco Locatelli, Luca Lo Nigro, Matteo Luciani, Chiara Messina, Concetta Micalizzi, Rosanna Parasole, Andrea Pession, Nicola Santoro, Anna Maria Testi, Daniela Silvestri, Giuseppe Basso, Giuseppe Masera, Valentino Conter
Journal: Blood (2007)
Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
Authors: Nurgul Ozgur Yurttas, Sevil Sadri, Dilek Keskin, Selin Berk, Isil Erdogan Oztunali, Fevzi Firat Yalniz, Ayse Salihoglu, Ahmet Emre Eskazan, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Teoman Soysal
Journal: Blood (2015)
A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.
Authors: Susan O'Brien, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, Adriano Venditti, Tove Flem Jacobsen, Karin Staudacher, Bo I Nilsson, Francis J. Giles
Journal: Blood (2009)
Cancer Registries Often Underestimate the True Incidence of CLL
Authors: Rosa Ruchlemer, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, Ariel Aviv, Ariella Arad, Osnat Bairey, Ohad Binyamini, Andre Braester, Riva Fineman, Neta Goldshmidt, Yair Herishanu, Naomi Rahimi-Levene, Lev Shvidel, Tamar Tadmor, Mona Yuklea, Aaron Polliack, Lital Keinan-Boker
Journal: Blood (2014)
<i>In Vitro</i> and <i>In Vivo</i> Evaluation of <sup>89</sup>Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
Authors: Ingrid J G Burvenich, Fook-Thean Lee, Nancy Guo, Hui K Gan, Angela Rigopoulos, Adam C Parslow, Graeme J O'Keefe, Sylvia J Gong, Henri Tochon-Danguy, Stacey E Rudd, Paul S Donnelly, Masakatsu Kotsuma, Toshiaki Ohtsuka, Giorgio Senaldi, Andrew M Scott
Journal: Theranostics (2016)

Background: DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific binding to DR5. DS-8273a is currently being used in clinical Phase I trials. This study evaluated the molecular imaging of DR5 expression in vivo in mouse tumor models using SPECT/CT and PET/MRI, as a tool for drug development and trial design. Methods: DS-8273a was radiolabeled with indium-111 and zirconium-89. Radiochemical purity, immunoreactivity, antigen binding affinity and serum stability were assessed in vitro. In vivo biodistribution and pharmacokinetic studies were performed, including SPECT/CT and PET/MR imaging. A dose-escalation study using a PET/MR imaging quantitative analysis was also performed to determine DR5 receptor saturability in a mouse model. Results:111In-CHX-A″-DTPA-DS-8273a and 89Zr-Df-Bz-NCS-DS-8273a showed high immunoreactivity (100%), high serum stability, and bound to DR5 expressing cells with high affinity (Ka, 1.02-1.22 × 1010 M-1). The number of antibodies bound per cell was 32,000. In vivo biodistribution studies showed high and specific uptake of 111In-CHX-A″-DTPA-DS-8273a and 89Zr-Df-Bz-NCS-DS-8273a in DR5 expressing COLO205 xenografts, with no specific uptake in normal tissues or in DR5-negative CT26 xenografts. DR5 receptor saturation was observed in vivo by biodistribution studies and quantitative PET/MRI analysis. Conclusion:89Zr-Df-Bz-NCS-DS-8273a is a potential novel PET imaging reagent for human bioimaging trials, and can be used for effective dose assessment and patient response evaluation in clinical trials.
OC-014 Extra Wide Angle View Colonoscope (EWAVE) has Superior Polyp Detection Rate When Compared to a Standard Colonoscope (SD): A Randomised Tandem Pre-Clinical Study: Abstract OC-014 Table 1
Authors: R Rameshshanker, A Wilson, P Tekkis, BP Saunders
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy screening with the removal of adenomas has been the preferred and most effective strategy to prevent colorectal cancer (CRC). However adenomas are often missed during colonoscopic examination, particularly on the proximal sides of folds and at the flexures. The prototype (EWAVE) Extra Wide Angle View colonoscope (Olympus, Tokyo, Japan) has a 147°–235° angle lateral/backward view lens and a standard 140° angle forward view lens. Views from both lenses are constructed and displayed as a single image. By improving visualisation behind the folds and flexures this new scope could increase the polyp detection rate (PDR). Objective is to compare the polyp detection rate between EWAVE and a standard colonoscope in a colonic model with simulated polyps. <h3>Methods</h3> Two colorectal (Koken, Japan) rubber colon models were prepared with 18 and 20 polyps of different size (520 mm) at various locations. Seventeen endoscopists, 14 gastroenterology trainees and 3 nurse endoscopists with varying levels of experience performed back to back examinations with the standard colonoscope and EWAVE scope. The order which they performed the procedure (i.e. EWAVE or SD first) was randomised using concealed envelopes. In order to minimise type 2 error, on the 2<sup>nd</sup> model the endoscopists performed the procedure in reverse order. <h3>Results</h3> There was no significant difference in mean insertion time (p = 0.8) or withdrawal time (p = 0.29) between EWAVE and standard colonoscope (Figure 1). Mean simulated PDR was significantly higher with EWAVE examination when compared to standard colonoscopic examination in both models (p = 0.026 and &lt;0.0001). Mean simulated PDR was significantly higher with EWAVE in comparison to the standard colonoscope for polyps in the mid transverse colon (79.4% vs 32.3%, p = 0.0002) and mid sigmoid colon (82.3% vs 52.9%, p = 0.0186). When the examination was carried out with the standard colonoscope followed by EWAVE, PDR was significantly higher in both models (p = 0.045 for model 1 and p &lt; 0.0001 for model 2). More significantly no difference was observed when the procedure was performed in the reverse order (p = 0.28 for model 1 and p = 0.08 for model’2). <h3>Conclusion</h3> Our non-clinical study showed significantly higher polyp detection rates with the novel extra wide angle colonoscope when colonoscopy was performed by moderately experienced colonoscopists. Further clinical trials appear warranted. <h3>Disclosure of Interest</h3> None Declared
Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL),
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Pietro Bulian, Francesco Buccisano, Annalisa Biagi, Benedetta Neri, Alessio Pio Perrotti, Antonella Zucchetto, Luca Maurillo, Pasquale Niscola, Adriano Venditti, Paolo de Fabritiis, Valter Gattei, Sergio Amadori
Journal: Blood (2011)
T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells
Authors: Miriam E. Mossoba, Jacopo Mariotti, Xiao-Yi Yan, Anu Gangopadhyay, Mathew Winterton, Marianna Sabatino, Hanh Khuu, Vicki Fellowes, Frances T. Hakim, David Stroncek, Susan Leitman, Bruce L Levine, Carl H. June, Daniel H Fowler
Journal: Blood (2010)
Studies in C4b-Deficient Mice Provide Further Evidence That Complement Cascade Orchestrates the Mobilization of Hematopoietic Stem/Progenitor Cells.
Authors: Anna Janowska-Wieczorek, Leah A. Marquez-Curtis, Danila Leontyev, Donald R. Branch, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2012)
IKZF1 Deletion Is Strongly Associated with Risk of Relapse in Intermediate Risk Group in JACLS ALL02 Cohort
Authors: Daisuke Asai, Toshihiko Imamura, Souichi Suenobu, Daiichiro Hasegawa, Takao Deguchi, Yoshiko Hashii, Kimikazu Matsumoto, Hirohide Kawasaki, Hiroki Hori, Akihiro Iguchi, Yoshiyuki Kosaka, Kouji Kato, Keizo Horibe, Keiko Yagi, Junichi Hara, Megumi Oda
Journal: Blood (2011)
Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution.
Authors: Theresia M Westers, Canan Alhan, Monique Terwijn, Claudia Cali, Yvonne FCM van der Veeken, Gerrit Jan Schuurhuis, Gert J Ossenkoppele, Arjan A van de Loosdrecht
Journal: Blood (2009)
Adhesive and Inflammatory Properties Are Increased in Blood Outgrowth Endothelial Cells From Patients with Sickle Cell Anemia
Authors: Tatiana M. Sakamoto, Carolina Lanaro, Vanessa Tonin Garrido, Margareth C. Ozelo, Sara T. Olalla-Saad, Nicola Conran, Fernando Ferreira Costa
Journal: Blood (2011)
Key Immune Cell Subsets Are Dysregulated in Patients with Myelofibrosis
Authors: Marco Romano, Lucia Catani, Daria Sollazzo, Martina Barone, Margherita Perricone, Elisa Zuffa, Eugenia Franchini, Nicola Polverelli, Lara Rossi, Emanuela Ottaviani, Giovanni Martinelli, Nicola Vianelli, Francesca Palandri
Journal: Blood (2014)
Standard Duration of Varicella Zoster Virus Prophylaxis May be Inadequate to Prevent Viral Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Front-Line Bendamustine Plus Rituximab
Authors: Joshua M. Allen, Lisa A. Rybicki, Paolo F. Caimi, Deepa Jagadeesh, Robert M. Dean, Brad Pohlman, Mitchell R. Smith, Matt Kalaycio, Brian T. Hill
Journal: Blood (2015)